Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Peter M, Szabó"'
Autor:
George M. Yousef, Jason Y. Lee, Sergey N. Krylov, Peter M. Szabó, Michael A.S. Jewett, Heba W.Z. Khella, Henriett Butz, Roy Nofech-Mozes, Michael Ordon, Qiang Ding, Robert Stewart, Antonio Finelli
Publikováno v:
European Urology Focus. 2:210-218
Apart from an invasive biopsy, currently no tools are available to confirm the diagnosis of clear cell renal cell carcinoma (ccRCC); this resulted in approximately 30% of patients being diagnosed with metastatic disease.To determine whether urinary m
Autor:
Peter M. Szabó, Henriett Butz, Attila Patócs, George M. Yousef, Roy Nofech-Mozes, Heba W.Z. Khella
Publikováno v:
Oncotarget
// Henriett Butz 1,2 , Peter M. Szabo 3 , Heba W.Z. Khella 1,2 , Roy Nofech-Mozes 1 , Attila Patocs 4 and George M. Yousef 1,2 1 Department of Laboratory Medicine and The Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, Toro
Autor:
Peter Csermely, János Kubisch, Andreas Bender, Tamas Korcsmaros, Katalin Lenti, Istvan Marczell, Krishna C. Bulusu, Dezső Módos, Dávid Fazekas, Johanne Brooks, Peter M. Szabó, Tibor Vellai
Publikováno v:
NPJ Systems Biology and Applications
npj Systems Biology and Applications, Vol 3, Iss 1, Pp 1-13 (2017)
npj Systems Biology and Applications, Vol 3, Iss 1, Pp 1-13 (2017)
Even targeted chemotherapies against solid cancers show a moderate success increasing the need to novel targeting strategies. To address this problem, we designed a systems-level approach investigating the neighbourhood of mutated or differentially e
Autor:
Attila Patócs, Fabio Rotondo, Roy Nofech-Mozes, Kalman Kovacs, Henriett Butz, Hala Girgis, Dina Boles, Lorna Mirham, George M. Yousef, Peter M. Szabó
Publikováno v:
Clinical Chemistry. 60:1314-1326
BACKGROUND The outcome of clear cell renal cell carcinoma (ccRCC) is still unpredictable. Even with new targeted therapies, the average progression-free survival is dismal. Markers for early detection and progression could improve disease outcome. ME
Autor:
Ivan Igaz, Zsolt Nagy, Peter M. Szabó, Attila Patocs, Pál Perge, Vince Kornél Grolmusz, Peter Igaz
Publikováno v:
Medical hypotheses. 99
Sporadic tumors of the pituitary, parathyroids and adrenal cortex are unique, as their benign forms are very common, but malignant forms are exceptionally rare. Hereditary forms of these tumors occur in multiple endocrine neoplasia syndrome type 1 (M
Autor:
Attila Patocs, Károly Rácz, Ilona Kovalszky, Peter M. Szabó, Peter Igaz, Kornélia Baghy, Zoltan K. Nagy, Pál Perge
Publikováno v:
Endocrine Abstracts.
Autor:
Michele G. Mehaffey, Seth M. Steinberg, Gini F. Fleming, Miguel A. Villalona-Calero, Jiuping Ji, Robert J. Kinders, P. Mickey Williams, William D. Walsh, David R. Gandara, James H. Doroshow, Peter M. Szabó, Ahrim Youn, Barbara A. Conley, Alice P. Chen, Daniel M. Sullivan, Richard M. Simon, Robert J. Morgan, Paul M. McGregor, Amit M. Oza, Michael Naughton, Shivaani Kummar, Chih Jian Lih, Deborah Allen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(7)
Purpose: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relative contribution of PARP inhibition to the observed clinic
Autor:
Adrienn Zsippai, Diana Szabo, Peter M. Szabó, Miklós Tóth, Peter Igaz, Michaela Luconi, Attila Patocs, Károly Rácz, Zoltan K. Nagy, Massimo Mannelli
Publikováno v:
Endocrine Abstracts.
Autor:
Károly Rácz, Attila Patocs, Kornélia Baghy, Peter M. Szabó, Peter Igaz, A. Falus, Diana Szabo, Ilona Kovalszky
Publikováno v:
Endocrine Abstracts.
Autor:
Adrienn, Zsippai, Diana Rita, Szabó, Peter M, Szabó, Zsófia, Tömböl, Melinda R, Bendes, Zoltán, Nagy, Károly, Rácz, Peter, Igaz
Publikováno v:
American journal of cancer research. 1(5)
Adrenocortical cancer is a rare tumor and its prognosis is poor. Although numerous tumor-associated genetic and signal transduction alterations have been described to date, its pathogenesis is still unclear. Hybridization-based DNA microarray approac